SCHEMBL29284129

SCHEMBL29284129

COC(=O)C1CCC(N2CCN(C)CC2)C1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.40
CHRNB2 P17787 2/20 0.39
CHRNA4 P43681 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
DPP4 P27487 1/20 0.38
DPP8 Q6V1X1 1/20 0.38
DPP9 Q86TI2 1/20 0.38
DPP7 Q9UHL4 1/20 0.38
BRD4 O60885 1/20 0.37
HTT P42858 1/20 0.37
CHRNB4 P30926 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNA7 P36544 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
ALDH1A1 P00352 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1700365 0.82 TP53 (0.39) TP53SMN1; SMN2DPP4DPP8DPP9
SCHEMBL28616258 0.82 TP53 (0.39) TP53SMN1; SMN2DPP4DPP8DPP9
SCHEMBL1700363 0.82 TP53 (0.39) TP53SMN1; SMN2DPP4DPP8DPP9
SCHEMBL30226498 0.79 SMN1; SMN2 (0.41) TP53SMN1; SMN2DPP4DPP8DPP9
SCHEMBL2942040 0.75 SMN1; SMN2 (0.50) TP53SMN1; SMN2POLBGAAALDH1A1
SCHEMBL3274422 0.75 SMN1; SMN2 (0.50) TP53SMN1; SMN2POLBGAAALDH1A1
SCHEMBL2942042 0.75 SMN1; SMN2 (0.50) TP53SMN1; SMN2POLBGAAALDH1A1
SCHEMBL15415489 0.75 KMT2A (0.49) SMN1; SMN2DPP4
SCHEMBL16752730 0.75 KMT2A (0.49) SMN1; SMN2DPP4
SCHEMBL7277249 0.74 CHRNB2 (0.47) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250011299-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2025-01-09 US disclosed
EP-4405343-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2024-07-31 EP disclosed
CN-118201915-A Pyridazinylamino derivatives as ALK5 inhibitors 奇斯药制品公司 2024-06-14 CN disclosed
WO-2023046698-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011299-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS ALK, TGFBR1, ACVR1 TP53 3357/4885CHRNB2 561/4885CHRNA4 804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.